|
|
|
03 May 2006 |
OncoGenex Announces Encouraging Data from a Phase I Study of Patients with Non-Small Cell Lung Cancer
|
|
03 May 2006 |
Enrollment Completed in Phase III Studies of Nexavar for Patients with Metastatic Melanoma and Liver Cancer
|
|
03 May 2006 |
U.S. FDA Approves Dacogen(TM) (Decitabine) For Injection
|
|
03 May 2006 |
NPS Announces Clinical Advancement of Calcilytics Program by Its Collaborator GlaxoSmithKline
|
|
03 May 2006 |
Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy) Study of ''Oral'' Entry Inhibitor SP-01A
|
|
03 May 2006 |
Cipher Receives FDA Response To CIP-Isotretinoin NDA Submission
|
|
03 May 2006 |
Chemokine Therapeutics Achieves Critical Milestone With the Start of a Phase Ib/II Human Clinical Trial in Cancer
|
|
03 May 2006 |
New Broad-spectrum Antibiotic Tygacil* (tigecycline) Receives Approval for Use in Europe Today
|
|
02 May 2006 |
SIGA Announces Initiation of Phase I Human Clinical Trials of Its Lead Smallpox Drug SIGA-246
|
|
02 May 2006 |
Telik Announces Initiation of New TELCYTA Phase 3 Clinical Trial and Updates Status of Ongoing Phase 3 Ovarian Cancer Clinical Trials
|
|
02 May 2006 |
PURE Bioscience and Therapeutics, Inc. Expand Silver Dihydrogen Citrate Pharmaceutical Product Development Initiative to Include Athlete's Foot, Nail Fungus and Antimicrobial Skin Wash Products
|
|
02 May 2006 |
Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006
|
|
02 May 2006 |
Myriad Genetics Begins Phase 1 Trial of Anti-Thrombin Drug MPC-0920
|
|
02 May 2006 |
FDA Fast Track Designation for Basilea's Novel Broad-spectrum Water-soluble Antifungal BAL8557
|
|
02 May 2006 |
Cephalon Receives Approvable Letter for NUVIGIL(TM) (armodafinil)
|
|
02 May 2006 |
ViroPharma Announces Presentation of Pharmacokinetic Data From HCV-796 Phase 1a Study
|
|
02 May 2006 |
FDA Approves Higher Dose Formulations of Diovan HCT(R) (valsartan/hydrochlorothiazide) for Treatment of High Blood Pressure
|
|
02 May 2006 |
FDA Approves Use of NEXIUM® in Children Ages 12 to 17 for Short-term Treatment of GERD
|
|
02 May 2006 |
Javelin Announces Initial Results of a Pilot Phase II Study Of Intranasal Ketamine In Postoperative Orthopedic Pain
|
|
02 May 2006 |
Corcept Therapeutics Completes Enrollment In Phase 3 Study For Treating Psychotic Major Depression
|
|
30 Apr 2006 |
Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
|
|
30 Apr 2006 |
Favorable Antiviral Activity and Improved Tolerability Demonstrated by Valopicitabine 200 mg/day in Combination with Pegylated Interferon in an Ongoing Phase IIb Trial in Treatment-Naive Genotype 1 Patients
|
|
30 Apr 2006 |
New Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients
|
|
29 Apr 2006 |
Johnson & Johnson Pharmaceutical Research & Development & Grunenthal GmbH to Initiate Phase III Trials of Novel Analgesic for Moderate-To-Severe Acute Pain
|
|
28 Apr 2006 |
Pfizer's Sutent Receives Positive Opinion in the European Union for Two Difficult-to-Treat Advanced Cancers
|
|
28 Apr 2006 |
Abbott's New Tablet Formulation of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From the European Medicines Agency
|
|
28 Apr 2006 |
Avanir Announces Neurodex Phase III Trial Results Published In Annals Of Neurology
|
|
28 Apr 2006 |
Acomplia® (rimonabant) recommended for approval in the European Union
|
|
28 Apr 2006 |
FibroGen Licenses Oral HIF-PH Inhibitors, Including FG-2216 and FG-4592, to Astellas for the Treatment of Anemia in Europe and Other Regions
|
|
28 Apr 2006 |
Neurocrine Biosciences Announces Positive Phase II Results With Its Orally Active GnRH Receptor Antagonist in Endometriosis
|
|
28 Apr 2006 |
Biotie To Submit MAA For Oral Nalmefene And Signs First Marketing Agreement In Europe
|
|
28 Apr 2006 |
Nexavar (R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
|
|
28 Apr 2006 |
NUCRYST Pharmaceuticals announces completion of patient enrollment in second Phase 2 clinical trial of topical cream for the treatment of atopic dermatitis
|
|
28 Apr 2006 |
AmpliMed Initiates Phase I Clinical Study of Benzimate in Patients with Advanced Refractory Cancer; New Formulation of Promising Cancer Drug Joins Amplimexon as Second Clinical-stage Compound in AmpliMed Portfolio
|
|
27 Apr 2006 |
Transition Therapeutics Receives Clearance to Initiate Phase I Clinical Trial with Alzheimer’s Disease Product AZD-103
|
|
27 Apr 2006 |
GIANT Study: Many more women affected by acute exacerbations of chronic bronchitis (AECBs) than widely believed
|
|
27 Apr 2006 |
Amicus Therapeutics Files Investigational New Drug Application For AT2101 For Gaucher Disease
|
|
27 Apr 2006 |
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
|
|
27 Apr 2006 |
A.P. Pharma Initiates APF530 Phase 3 Clinical Trial; IRB Approval Received
|
|
27 Apr 2006 |
Oglemilast, Glenmark’s lead molecule for Asthma/COPD, enters Phase II
|
|
27 Apr 2006 |
US submission of Exforge® accepted for review by the FDA as a new therapy option for high blood pressure
|
|
27 Apr 2006 |
Nuvo completes analysis of long-term safety data for Pennsaid (R)
|
|
27 Apr 2006 |
Completion of ANA380 Dosing in Phase II Clinical Trial Confirms Robust Activity Against Lamivudine-Resistant Hepatitis B Virus
|
|
27 Apr 2006 |
Point Therapeutics Presents Talabostat's Novel Dual Mechanism of Action During Research and Development Day
|
|
27 Apr 2006 |
New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
|
|
27 Apr 2006 |
Adherex Initiates Clinical Proof-Of-Mechanism Trial of Eniluracil
|
|
27 Apr 2006 |
CTA002, A Novel Vitamin D Analog, Shows Significant Antitumor Activity In Human Neuroblastoma
|
|
27 Apr 2006 |
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
|
|
27 Apr 2006 |
SuperGen Announces Interim Results of Orathecin(TM) Combination Trial in Pancreatic Cancer
|
|
27 Apr 2006 |
Chronogen Receives Approval to Proceed with a Phase I/II Clinical Trial
|
| |
|
Results 5151 - 5200 of 5705 |
